Caleco Pharma Corp.
OTC Bulletin Board : CAEH

Caleco Pharma Corp.

February 23, 2010 16:15 ET

Market Demand for Caleco's Liver Health Formulation

Company reports on early success of its lead product to inhibit the growth of Hepatitis C virus

BELLINGHAM, WASHINGTON--(Marketwire - Feb. 23, 2010) - Caleco Pharma Corp. (the "Company" or "Caleco") (OTCBB:CAEH)(FRANKFURT:T3R)(WKN: A0N9Y0) (, a biopharmaceutical and consumer health products company that identifies and develops biotech products, today provides insight into the development strategy for its lead, patent protected product line that targets a segment of the market that includes millions of people suffering from various liver maladies, especially the Hepatitis C Virus (HCV). 

"Pre-clinical research and an observational study have indicated that products derived from the company's proprietary "Liver Health" formulation, exhibit anti-viral activity," said John Boschert, Caleco's President and CEO. "We will continue pre-clinical work with these compounds, CPC.12115HP201 and CPC.12115HP202 in 2010 focusing on developing and testing additional derivatives as well as further compound isolation work on the parent herbal formulation. With the anti-viral activity profiles having been demonstrated in two bioassay systems, and considering the observed clinical effects of the parent herbal formulation, the Corporation believes continued preclinical development work is warranted."

The company is pursuing a two-tiered strategy to bring the parent herbal formulation to market while continuing development of CPC.12115HP201 and CPC.12115HP202. The company is actively engaged in pre-commercialization projects related to bringing the proprietary "Liver Health" formulation to worldwide markets as an oral health supplement following additional clinical trials expected to start in the first half of 2010. In addition, derivatives of the parent herbal formulation are being considered for oral supplement development targeted at immune system enhancement and as dermatologic products for use in common chronic dermatologic conditions. 

To date, the Company's intellectual property covering the "Liver Health" formulations is comprised of patent applications in the United States, Europe and Canada and four European Drug Master File applications.

Additional information is available on the company's website at:

About Caleco Pharma Corp.

Caleco Pharma is focused on the ongoing research and development of its pipeline of over-the-counter and prescription medications including its proprietary antiviral and "Liver Health" OTC formulations. In addition Caleco Pharma is developing Dermatological Products based on the active ingredients found in its proprietary formulation. To date, Caleco Pharma's intellectual property covering the Liver Health formulations and derivatives consists of patent applications in the United States, Europe and Canada and four European Drug Master File applications.

Caleco Pharma's shares are traded in the United States on the OTC Bulletin Board (OTCBB:CAEH) and in Germany on the Frankfurt Stock Exchange (WKN: A0N9Y0/ Symbol: T3R.FSE).

This press release may contain, in addition to historic information, forward-looking statements. These statements may involve known and unknown risks and uncertainties and other factors that may cause the actual results to be materially different from the results implied herein. In particular, there are no assurances that: (i) the United States Patents and Trademarks Office will grant Caleco Pharma a patent in connection with its current patent applications; (ii) Caleco Pharma will be able to manufacture and produce its products or that its products will be effective; or (iii) it will be able to carry out any pre-clinical or clinical trials of its products. (iv) the Company will be able to obtain additional financing in order to meet the costs of the clinical studies of the "Liver Health" formulation and (v) the Company will be able to control the costs of the clinical studies of the "Liver Health" formulation. Readers are cautioned not to place undue reliance on the forward-looking statements made in this press release.

Contact Information